Loading company
Supernus Pharmaceuticals, Inc.
SUPN · Nasdaq · ·
Next earnings: November 3, 2026
$44.01-1.2%Sep 29 close
- 1M
- +0.6%
- 6M
- -10.8%
- 1Y
- -7.9%
- 5Y
- +57.4%
SUPN · Nasdaq · ·
Next earnings: November 3, 2026
$44.01-1.2%Sep 29 close
Supernus Pharmaceuticals, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $219.1M | $165.5M | +32.40% |
| Profit | -$58.4M | $22.5M | -359.44% |
| Profit per share | -$1.01 | $0.40 | -352.50% |
| Free Cash Flow | -$5.4M | $58.1M | -109.26% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our first-half 2026 results reflect the continued strength and sustained momentum of our growth products and continued execution on our commercial strategy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Supernus Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Supernus Pharmaceuticals, Inc. has no earnings call transcript available.